FORTEX​PHARMA

IPAMORELIN

Selective Growth Hormone Secretagoge 2000mcg 

​

Ipamorelin is a growth hormone secretagogue from the GHRP class (Growth Hormone Releasing Peptides). This is a third generation GHRP. It was developed alongside a series of other modified derivatives of a first generation GHRP. Like other GHRPs, ipamorelin binds and activates growth hormone secretagogue receptor 1a (GHSRIa). This supports the pulsatile release of growth hormone, and in turn potentially IGF-1. As a stimulator of GH release, ipamorelin appears to be moderately potent. It is stronger than GHRP-6, but less effective than GHRP-2. However, it does have unique properties regarding selectivity that make this drug of interest, discussed below. In the fitness community, ipamorelin is most often used for the support of muscle growth and fat loss. Ipamorelin is highly selective for the stimulation of growth hormone release. This means minimal spillover effects on other systems. For starters, ipamorelin has been shown to only slightly increase ACTH (adrenocorticotropic hormone) and cortisol levels. These increases are far less notable than with the non-selective GHRPs to come before it, and no more in intensity than the natural hormone GHRH. Further, this effect does not appear to be dose dependent. Related side effects are unlikely. Further, ipamorelin appears to have negligible effect on appetite. Drugs of the GHRP class often mimic ghrelin's tendency to strongly stimulate hunger, which can be problematic while dieting. This makes ipamorelin more practical for this purpose.

​

When used for physique- or performance-enhancing purposes, ipamorelin is usually administered at a dosage of 0.2 to 0.3 mg (200-300 meg) per injection.This may be given 1 -3 times daily. If single episode dosing is preferred, this is taken before sleep, sometimes at a higher dose (up to 500 mcg). Day dose(s) are taken on an empty stomach, 30-60 minutes before a meal. This is to preserve optimal GH release, as elevated plasma fatty acids and/or glucose may blunt the GH elevating effects of GHRPs. Total daily dosage generally does not exceed 900 mcg.

It is common to taper up the dosage, beginning with only 200 meg per injection. This may be increased by 50 mcg every few days, until a stable peak dosage is reached. Cycles of ipamorelin usually last 3-4 months in length, though programs of 6 months or longer are not uncommon.